Milestone Scientific Inc. (AMEX:MLSS)‘s stock had its “buy” rating restated by analysts at Maxim Group in a research report issued to clients and investors on Tuesday, StockTargetPrices.com reports. They currently have a $4.00 price target on the medical instruments supplier’s stock. Maxim Group’s price objective suggests a potential upside of 158.06% from the stock’s previous close.

Milestone Scientific (AMEX MLSS) traded up 1.64% during trading on Tuesday, reaching $1.55. The company’s stock had a trading volume of 50,321 shares. Milestone Scientific has a 52 week low of $1.10 and a 52 week high of $3.04. The firm has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.42. The firm’s market capitalization is $95.27 million.

WARNING: “Milestone Scientific Inc. (MLSS) Earns Buy Rating from Maxim Group” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/18/milestone-scientific-inc-mlss-earns-buy-rating-from-maxim-group.html.

About Milestone Scientific

Milestone Scientific Inc (Milestone) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types.

Stock Target Prices

Receive News & Ratings for Milestone Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.